CYP19A1 and breast cancer: Change in the proliferation marker Ki67 (a marker of a rapid increase in cell numbers as measured on tumour tissue) has been shown to be predictive of response to treatment with aromatase inhibitors and can be used as an indicator of risk of breast cancer occurring again (recurrence).